Examkin

Soru

Zorluk: ZorPsychopharmacology and Psychological Therapies

A 24-year-old man with a history of schizophrenia is brought to the emergency department from a residential psychiatric facility due to profound muscle stiffness, confusion, and diaphoresis. His vital signs show a temperature of 39.8°C (103.6°F), blood pressure of 165/100 mmHg, and heart rate of 122/min. Physical examination reveals generalized "lead-pipe" rigidity and coarse tremors. He was recently transitioned to intramuscular fluphenazine decanoate. Laboratory studies reveal a serum creatine kinase level of 5,200 U/L. Arrange the following steps in the most appropriate chronological sequence for the management of this patient's current condition and his subsequent long-term psychiatric care.

  1. 1Discontinue the administration of fluphenazine and any other dopamine receptor antagonists.
  2. 2Initiate aggressive supportive care with intravenous hydration, active cooling, and correction of electrolyte abnormalities.
  3. 3Administer specific medical therapy such as bromocriptine, amantadine, or dantrolene.
  4. 4Maintain a psychotropic-free observation period of at least two weeks following complete symptom resolution.
  5. 5Cautiously initiate an atypical antipsychotic with lower extrapyramidal symptom liability, such as quetiapine.

Cevap

The correct sequence begins with the immediate discontinuation of the offending dopamine antagonist, followed immediately by aggressive supportive care, and then specific pharmacologic antidotes if necessary. After clinical resolution, a two-week washout period is required before cautiously restarting a lower-risk atypical antipsychotic.
The management of Neuroleptic Malignant Syndrome (NMS) follows a strict timeline of immediate, short-term, and long-term interventions. The absolute first step is the discontinuation of the offending agent (fluphenazine). This is followed by intensive supportive care (cooling, hydration) to prevent complications like acute kidney injury from rhabdomyolysis. If the patient does not respond adequately to supportive measures, specific pharmacologic therapies such as bromocriptine (dopamine agonist) or dantrolene (ryanodine receptor antagonist) are administered. Following successful treatment and resolution of symptoms, standard psychiatric guidelines dictate a minimum two-week washout period to allow the syndrome to completely clear and to allow receptor equilibration. Finally, when re-initiating treatment for the underlying schizophrenia, a medication with a lower risk of extrapyramidal symptoms and NMS, such as an atypical antipsychotic (e.g., quetiapine), should be selected and titrated cautiously.

Adım Adım Çözüm

1
Diagnose the acute condition based on the clinical presentation.
The patient has Neuroleptic Malignant Syndrome (NMS), characterized by altered mental status, autonomic instability, hyperthermia, and lead-pipe rigidity in the setting of fluphenazine use.
Accurate diagnosis dictates the specific treatment pathway and urgency of intervention.
2
Determine the acute management algorithm for NMS.
The sequence is to first remove the trigger (stop fluphenazine), second stabilize physiology (IV fluids, cooling blankets), and third use targeted antidotes (bromocriptine or dantrolene) if the patient remains severely symptomatic.
This stepwise approach minimizes toxicity while addressing life-threatening complications like rhabdomyolysis and hyperthermia.
3
Determine the post-recovery psychiatric pharmacotherapy protocol.
After NMS resolves, a mandatory 2-week washout period must be observed before utilizing a lower-risk antipsychotic (e.g., quetiapine, clozapine) to manage the underlying schizophrenia.
NMS has a high recurrence rate if antipsychotics are restarted prematurely or if high-potency agents are reused.

Anahtar Kavram

Algorithm for acute treatment and post-recovery pharmacotherapy of Neuroleptic Malignant Syndrome (NMS).
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Psychopharmacology and Psychological Therapies

Bu konudan daha fazla soru